427878-41-9

Basic information

• Product Name: ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE
• Synonyms: ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE;4-Chloro-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester;Ethyl 4-chloro-5-methylpy...;ethyl 4-chloro-5-Methyl-pyrrolo[1,2-f][1,2,4]triazine-5-carboxylate, ethyl 4-chloro-5-Methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate;ethyl 4-chloro-5-Methyl-4a,5-dihydropyrro lo[1,2-f][1,2,4]triazine-6-carboxylate;4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE
• CAS NO: 427878-41-9
• Molecular Formula: C₁₀H₁₀ClN₃O₂
• Molecular Weight: 239.661
• Mol File: 427878-41-9.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Density: 1.42g/cm3
• Refractive Index: 1.633
• Storage Temp.: 2-8°C
• PKA: -3.72±0.30(Predicted)
• CAS DataBase Reference: ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE(427878-41-9)
• EPA Substance Registry System: ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE(427878-41-9)

Safety Data

• Hazardous Substances Data: 427878-41-9(Hazardous Substances Data)

Usage

General Description

ETHYL 4-CHLORO-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE is a chemical compound that is categorized under the class of Pyrrolo[2,1-f][1,2,4]triazines, which are polycyclic aromatic compounds containing a pyrrole ring fused to a 1,2,4-triazine ring system. This specific compound contains an ethyl group, a chloro group, and a carboxylate group, giving it distinct properties. There are no significantly noted uses or applications of this chemical readily available in scientific literature, mostly because it is a fairly complex molecule. The safety, toxicity, and environmental impact are also not widely studied or established due to its rarity and less frequent use. As such, it's mostly encountered in chemical research or advanced organic synthesis.

InChI:InChI=1/C10H10ClN3O2/c1-3-16-10(15)7-4-14-8(6(7)2)9(11)12-5-13-14/h4-5H,3H2,1-2H3

Upstream product

• 427878-70-4 ethyl 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 5448-16-8 3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 427878-69-1 1-amino-3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 21295-50-1 phosphorus (III) oxychloride 
• 427878-70-4 C₁₀H₁₁N₃O₃ 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 1028330-33-7 C₂₅H₂₂F₃N₅O₃ 
• 427877-66-5 ethyl 4-((5-(methoxycarbamoyl)-2-methylphenyl)-amino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 856667-80-6 4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 623154-41-6 C₂₀H₂₃N₅O₃ 
• 623155-58-8 C₂₂H₂₈FN₅O₃ 
• 623152-12-5 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-pyrrolo[1,2-f][1,2,4]triazine-6-carboxylic acid 
• 427878-59-9 N-n-propyl-4-[(2-methyl-5-amino)aminophenyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide 
• 427878-58-8 N-n-propyl-4-[(2-methyl-5-nitro)phenylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide 
• 427878-57-7 5-Methyl-4-[(2-methyl-5-nitrophenyl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 623153-27-5 C₂₇H₃₀N₈O₃ 
• 623155-40-8 C₂₅H₂₅N₇O₄ 
• 623152-98-7 C₂₇H₂₃N₇O₂ 
• 623154-45-0 C₂₂H₂₆N₆O₄ 
• 623152-13-6 N-butyl-4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide 

Relevant articles and documents

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv